| scholarly article | Q13442814 |
| P50 | author | Nimish Patel | Q45981115 |
| P2093 | author name string | A Evans | |
| S Ferro | |||
| T P Lodise | |||
| M Bonafede | |||
| S Harrington | |||
| K Stellrecht | |||
| P Lubanski | |||
| P2860 | cites work | Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing | Q34630593 |
| Mechanisms of antibiotic resistance in Staphylococcus aureus | Q34657311 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy | Q36328976 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin | Q42042890 | ||
| Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. | Q42112516 | ||
| Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus | Q43251091 | ||
| Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. | Q46879391 | ||
| Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. | Q51785920 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| gram-positive bacteria | Q857288 | ||
| P1104 | number of pages | 4 | |
| P304 | page(s) | 5141-5144 | |
| P577 | publication date | 2009-10-05 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus | |
| P478 | volume | 53 |
| Q89621264 | A Single Step in vitro Bioassay Mimicking TLR4-LPS Pathway and the Role of MD2 and CD14 Coreceptors |
| Q42855424 | Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies |
| Q33997671 | Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs |
| Q50196433 | Selection of appropriate analytical tools to determine the potency and bioactivity of antibiotics and antibiotic resistance |
| Q42250762 | Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. |
Search more.